logo-loader
BioPorto

BioPorto private placement of more than 9.2 million shares fully subscribed

The aggregate subscription price for the new shares is DKK36,748,610, or US$5.5 million

Kidney
BioPorto is based in Hellerup, Denmark

BioPorto A/S (CPH:BIOPOR) announced Monday that a private placement of more than 9.2 million shares is fully subscribed.

The aggregate subscription price for the new shares is DKK36,748,610 (US$5.5 million), which will be paid before the end of June, according to a statement.

BioPorto expects to complete the share capital increase and issue the new shares in early July.

The company has submitted an application to the US Food and Drug Administration for approval of its proprietary NGAL Test that assesses the risk of acute kidney injury in children under 21.

BioPorto, based in Hellerup, Denmark, also plans to seek FDA clearance of the NGAL Test for use in adults in the second half of 2019.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: BioPorto

Price: £0.00

Market: NASDAQ OMX
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read